Expertise in
22
conditions

Dr. Jonathan King

Hematology | Oncology
Grand Valley Oncology
688 23 1/2 Rd, 
Grand Junction, CO 
Offers Telehealth
Expertise in
22
conditions
Grand Valley Oncology
688 23 1/2 Rd, 
Grand Junction, CO 

Overview

Jonathan King is a Hematologist and an Oncologist in Grand Junction, Colorado. Dr. King is highly rated in 22 conditions, according to our data. His top areas of expertise are Metastatic Pleural Tumor, Familial Pancreatic Cancer, Lung Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Medical College Of Wisconsin

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

Intermountain Health St. Mary's Regional Hospital
Community Hospital
Montrose Regional Health
Moab Regional Hospital
Delta County Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Grand Valley Oncology
688 23 1/2 Rd, Grand Junction, CO 81505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
View 9 Less Clinical Trials

4 Total Publications

Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review.
Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review.
Journal: Journal of pain and symptom management
Published: February 17, 2015
Similar Doctors
Expertise in
16
conditions
Dr. Daniel Couriel
Hematology
Expertise in
16
conditions
Dr. Daniel Couriel
Hematology

Bmt - Grand Valley Oncology

2596 F Rd, 
Grand Junction, CO 
 (0.1 miles away)
970-254-3180
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Couriel is a Hematologist in Grand Junction, Colorado. Dr. Couriel is highly rated in 16 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant. Dr. Couriel is currently accepting new patients.

Expertise in
5
conditions
Dr. Kristina Goutsouliak
Hematology | Oncology
Expertise in
5
conditions
Dr. Kristina Goutsouliak
Hematology | Oncology

Grand Valley Oncology

688 23 1/2 Rd, 
Grand Junction, CO 
 (11.5 miles away)
970-644-3180
Languages Spoken:
English
See accepted insurances

Kristina Goutsouliak is a Hematologist and an Oncologist in Grand Junction, Colorado. Dr. Goutsouliak is highly rated in 5 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Pseudomyxoma Peritonei.

Expertise in
14
conditions
Dr. Glenn Bigsby
Oncology
Expertise in
14
conditions
Dr. Glenn Bigsby
Oncology

Grand Valley Gynecologic Oncology

688 23 1/2 Rd Ste 201, 
Grand Junction, CO 
 (11.5 miles away)
970-644-3821
Languages Spoken:
English
See accepted insurances

Glenn Bigsby is an Oncologist in Grand Junction, Colorado. Dr. Bigsby is highly rated in 14 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Hysterectomy.

Frequently Asked Questions about Dr. Jonathan King

How do I make an appointment with Dr. Jonathan King?

You can book an appointment with Dr. Jonathan King by calling their office at 970-644-3180. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan King a top-rated expert for Metastatic Pleural Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan King is classified as an Distinguished expert for Metastatic Pleural Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan King specialize in?

While Dr. Jonathan King is a Hematology, they have specific expertise in Metastatic Pleural Tumor, Familial Pancreatic Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jonathan King participate in research or clinical trials?

Yes. Dr. Jonathan King has published 4 articles and abstracts on conditions like Metastatic Pleural Tumor. You can view a list of Dr. Jonathan King's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan King accept my insurance?

Dr. Jonathan King accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 970-644-3180 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. King's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile